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Abstract
Background: Vestibular schwannomas are benign tumors that arise from Schwann cells in the VIII cranial pair and usually
present NF2 gene mutations and/or loss of heterozygosity on chromosome 22q. Deregulation has also been found in
several genes, such as ERBB2 and NRG1. MicroRNAs are non-coding RNAs approximately 21 to 23 nucleotides in length that
regulate mRNAs, usually by degradation at the post-transcriptional level.
Methods: We used microarray technology to test the deregulation of miRNAs and other non-coding RNAs present in
GeneChip miRNA 1.0 (Affymetrix) over 16 vestibular schwannomas and 3 control-nerves, validating 10 of them by qRT-PCR.
Findings: Our results showed the deregulation of 174 miRNAs, including miR-10b, miR-206, miR-183 and miR-204, and the
upregulation of miR-431, miR-221, miR-21 and miR-720, among others. The results also showed an aberrant expression of
other non-coding RNAs. We also found a general upregulation of the miRNA cluster located at chromosome 14q32.
Conclusion: Our results suggest that several miRNAs are involved in tumor formation and/or maintenance and that global
upregulation of the 14q32 chromosomal site contains miRNAs that may represent a therapeutic target for this neoplasm.
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Introduction
Schwannomas are benign tumors that arise from Schwann cells
in the peripheral nerves. These tumors often originate from the
vestibular nerve, and although they are histologically benign,
vestibular schwannomas may cause hearing loss, tinnitus, facial
palsy, and when large enough, brain stem compression and even
death. Vestibular schwannomas may appear unilaterally but may
also appear bilaterally when associated with neurofibromatosis
type 2 syndrome (NF2). Patients with NF2 also develop other
tumors such as meningiomas and gliomas [1]. The molecular
hallmark of the disease is the biallelic inactivation of the tumor
suppressor NF2 gene by several mechanisms [2], such as mutation
or loss of heterozygosity (LOH) of chromosome 22 where this gene
is hosted (i.e., 22q12.2). Since the first description of monosomy 22
in schwannomas by cytogenetic analyses [3], other genetic
alterations in these tumors have been identified, including
chromosomal gains of 9q34 and 17q and losses of 1p [4–6]. For
an extensive review, see citation [7]. Contrary to non-head and
neck schwannomas, sporadic vestibular schwannomas have shown
no mutations on BRAF, EGFR, PIK3CA or KRAS [8]. Controversial
findings on epigenetic aberrant methylation of NF2 in schwanno-
mas have been provided [9–12], and data on promoter
methylation of tumor-related genes have also been described
[13]. The NF2 gene encodes for Merlin or Schwannomin [14,15],
a protein that shares sequence homology with members of the
ezrin/radixin/moesin (ERM) family. Merlin is involved in an
array of signaling pathways, such as the suppression of tumor-
igenesis by its entering into the nucleus and binding to DCAF1
through the blocking of CRL4DCAF1 action [16], or downregula-
tion of membrane levels of ErbB2, ErbB3 and EGFR upon cell-to-
cell contact [17,18]. Using microarray technology in schwanno-
mas, complete genome expression analysis is possible, and several
regulatory pathways and specific genes, such as CAV1, have been
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found to display an altered expression pattern [19–23]. Micro-
RNAs (miRNAs) are endogenous, non-coding RNAs 21 to 23
nucleotides in length that regulate gene expression at the post-
transcriptional level by, among other mechanisms, binding and
repressing target mRNAs [24]. Each miRNA is able to regulate
thousands of mRNAs, and each miRNA acts in a tissue-specific
manner [25]. Overexpression of miRNAs may involve tumor
development by silencing certain tumor suppressor genes. On the
other hand, underexpression of miRNAs may cause tumor
progression by upregulating target oncogenes. Thus, miRNAs
might be considered oncogenes or tumor suppressor genes in and
of themselves. A wide variety of tumors have been found with
altered miRNA expression, such as breast cancers [26], hepato-
cellular carcinomas [27], osteosarcomas [28] and many others
[29]. Aberrant expression patterns in miRNAs have also been
described in tumors that affect the nervous system, such as gliomas
and meningiomas [30,31].
In schwannomas, the regulation of two miRNAs has been
associated with tumorigenesis: miR-21 upregulation [32] and
miR-7 downregulation [33], which suggests that deregulation of
these small RNAs plays a role in the development of these tumors.
In the light of these results, we performed a microarray analysis on
16 schwannomas and 3 control-nerves for non-coding RNAs, in
order to identify new targets for the disease.
Materials and Methods
Patient Samples
The study group consisted of 16 patients who underwent
surgery at our center for the removal of vestibular Schwannoma.
Fifteen of these patients presented sporadic schwannomas and 1
sample (tumor S1) was from a patient diagnosed with NF2. The
population included 7 women and 9 men. The mean age of the
patients was 45.2614.9 years. The local ethics review board of the
University Hospital La Paz approved the study protocol, which
was based on the principles of the Declaration of Helsinki. All
Figure 1. Three dimensional representation of the Principal
Component Analysis of the 16 schwannomas (blue dots
corresponding to sporadical and red dot to the NF2 patient)
and the 3 control nerves (green dots).
doi:10.1371/journal.pone.0065868.g001
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patients received detailed information on the study and provided
their written informed consent prior to their inclusion in the study.
DNA/RNA Preparation
DNA was isolated using the Wizard Genomic DNA Purification
Kit (Promega). DNA was also extracted from the corresponding
patients’ peripheral blood. Total RNA was extracted using the
mirVana miRNA Isolation Kit (Ambion, CA, USA). A hypoglossal
ansa cervicalis nerve and two auricular nerves from non-tumoral
patients were used as control samples.
Mutational and MLPA Analysis of NF2 and LOH of
Chromosome 22q
We performed a mutational analysis of the NF2 gene by
dHPLC/PCR and a specific NF2 SALSA of MLPA (MRC-
Holland) and tested the LOH status of chromosome 22q. In brief,
the LOH of chromosome 22q was tested using 5 microsatellite
markers (D22S275, D22S264, D22S929, D22S268 and D22S280
located at 22q11-q12.3). For the PCR/dHPLC analysis of the NF2
gene, a set of 15 primer pairs were selected using the standard
PCR method and the dHPLC manufacturer’s protocols. For the
MLPA analysis, SALSA P044, which contains probes for all NF2
exons, was used. Complete procedures were described previously
[34].
miRNA Expression Array
We used the GeneChip miRNA 1.0 array (Affymetrix) with
coverage of miRBase v.11. The array contains 4 [35] probe sets
for mature miRNA and is able to detect the expression of 847
human mature miRNAs and 922 small nucleolar RNAs
(snoRNAs) and small Cajal body-specific RNAs (scaRNAs).
Hybridization targets were prepared from 500 ng of total RNA
using the FlashTag Biotin HSR Kit (Genisphere). The labeled
samples were hybridized to GeneChip miRNA arrays (Affymetrix).
GeneChips were scanned in a GeneChip Scanner 3000 (Affyme-
trix). CEL files were generated from DAT files using AGCC
software (Affymetrix). To generate the log2 expression estimates,
the overall array intensity was normalized between the arrays, and
the probe intensity for all probes in a probeset were summarized to
a single value using the RMA (Robust Multichip Average)
algorithm [36]. The arrays were processed at the IRB Barcelona
Functional Genomics Core Facility. The microarray data was
entered into the NCBI Gene Expression Omnibus database and
are accessible through GEO Series accession number GSE43571.
Statistical Array Analysis
Given that the 19 samples were processed in two separate
batches, with controls and tumors in both, the batch-removal tool
of the Partek Genomic Suite 6.6 was used to remove the batch
effect. We also used this software in order to include genes as
deregulated, and we selected those genes with at least a 2-fold
change in expression and a p,0.05 cutoff in the one-way ANOVA
test. The rest of statistical analyses were performed using
MultiExperiment Viewer (MeV) [37]. Principal component
analysis (PCA) was performed by eigenvalue decomposition of
the 3 principal components for three-dimensional classification of
the samples, and an unsupervised hierarchical cluster by Pearson’s
correlation was selected to group the samples and the deregulated
miRNAs. We used the mirWalk (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/index.html) and DAVID
(http://david.abcc.ncifcrf.gov/) web tools in order to predict the
biological meaning of the deregulated miRNAs [38,39]. As NF2
vestibular schwannoma had the same way as the other tumors, we
decided to include it in the statistical study.
Validation by qRT-PCR
For validation by miRCURY locked nucleic acid (LNA)TM
Universal RT microRNA PCR protocol qRT-PCR (Exiqon), we
used the 3 control nerves and 7 of the 16 Schwannoma chosen at
random. A total of 10 miRNAs with aberrant expression were
selected based on potential pathways of interest and/or chromo-
somal location (hsa-miR-1, hsa-miR-10b, hsa-miR-133b, hsa-
miR-183, hsa-miR-206, hsa-miR-221, hsa-miR-370, hsa-miR-
431, hsa-miR-493 and hsa-miR-720). The cDNA synthesis and
Figure 2. Hierarchical cluster by Pearson’s correlation of all 19
samples (16 schwannomas and 3 control nerves) and miRNAs
matching the criteria established as deregulated (2-fold
change in expression and a p,0.05 cutoff by one-way ANOVA).
doi:10.1371/journal.pone.0065868.g002
Table 1. The top 30 upregulated miRNAs obtained by
microarray analysis, ordered by positive fold-change in
schwannomas.
miRNA p-value Fold-Change
hsa-miR-431 5.47E-09 29.93
hsa-miR-720 4.96E-05 16.40
hsa-miR-34a* 2.73E-09 14.80
hsa-miR-221* 1.04E-09 9.96
hsa-miR-21 0.00116 9.71
hsa-miR-493 4.23E-07 8.48
hsa-miR-409-5p 9.25E-07 8.31
hsa-miR-363* 0.00010 8.09
hsa-miR-363 4.86E-09 8.05
hsa-miR-154 2.85E-05 7.53
hsa-miR-654-3p 0.00001 7.45
hsa-miR-20b* 3.33E-08 7.14
hsa-miR-543 3.29E-05 6.79
hsa-miR-377* 5.19E-06 5.63
hsa-miR-758 0.00057 5.63
hsa-miR-22* 5.70E-05 5.51
hsa-miR-127-3p 9.35E-07 5.42
hsa-miR-542-5p 0.00140 5.34
hsa-miR-200a 0.00028 5.31
hsa-miR-34a 4.27E-13 5.23
hsa-miR-224 0.00052 5.23
hsa-let-7i* 5.30E-06 5.17
hsa-miR-409-3p 9.77E-06 4.98
hsa-miR-221 1.23E-12 4.82
hsa-miR-184 0.01893 4.73
hsa-miR-181a-2* 2.89E-06 4.65
hsa-miR-493* 0.00094 4.65
hsa-miR-410 0.00096 4.47
hsa-miR-222 1.28E-10 4.47
hsa-miR-181c* 1.35E-07 4.30
doi:10.1371/journal.pone.0065868.t001
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real-time amplification were performed as recommended by the
manufacturer. All tests were performed in duplicate.
The calculation of gene expression was conducted as follows:
Average cycling threshold (Ct) values were obtained using SDS 2.2
software (Applied Biosystems). The maximum Ct value was set at
40. Ct values were normalized using two housekeeping non-coding
RNAs extracted from data obtained in arrays (SNORD49A and
hsa-miR-130). The relative expression level of each target gene
was expressed as DCt = Ctref–Ctgene [40]. Reference-normalized
expression measurements were adjusted by defining the lowest
expression value as 0, with subsequent 1-unit increases reflecting
an approximate doubling of the RNA. The non-parametric Mann-
Whitney-Wilcoxon test at p,0.05 coupled with the Benjamini-
Hochberg correction test was used to calculate the significance of
differences between the control samples and the schwannomas.
Results
Allelic Status of 22q and Mutational Analysis of NF2
A total of 9 samples (56%) presented 22q LOH using
microsatellite markers. Eight of the schwannomas (50%) had
NF2 sequence mutations detected by PCR/dHPLC, and 10 of the
schwannomas (62%) had NF2 sequence mutations detected by the
combined MLPA and PCR/dHPLC analysis. In 7 cases, LOH
was concomitant with either MLPA or PCR/dHPLC alteration.
In 4 cases, no alterations were found. We found no mutations in
the patients’ peripheral blood, with the exception of the NF2
patient. The individual results are shown in Table S1.
Deregulation in miRNAs
When the control nerves and the schwannomas were compared
using the one-way ANOVA at p,0.05 and with at least a 2-fold
change, we found 176 deregulated miRNAs from a total of 847
human miRNAs available in the array. Of these, 119 (14%) were
found to be upregulated and 57 (6.7%) were downregulated. The
top 30 of each group are shown in Tables 1 and 2, and the full
results of the deregulation can be seen in Table S2. The PCA
showed a clear distinction between the control nerves and the
schwannomas, and the tumor from the NF2 patient grouped
together with the other schwannomas (Figure 1). The hierarchical
cluster of deregulated genes showed no major differences at the
miRNA level between the schwannomas (included that tumor
from a NF2 patient) but showed differences with respect to the
controls (Figure 2).
The chromosomal location of the miRNA affected by dereg-
ulation is shown in Table 3. Chromosome 14 was the most
affected, with 52% of all miRNAs located on this chromosome
deregulated; all of these miRNAs were overexpressed, but one was
downregulated. Chromosome X also presented a high degree of
deregulation, with more than 27% of all miRNAs in this
chromosome showing aberrant expression. Other chromosomes
displaying significant rates of abnormally expressed miRNAs were
chromosome 1 (28%), chromosome 7 (26%) and, although fewer
miRNA probes were available in the array for this study,
chromosome 6 (29%) and 18 (33%).
Deregulation in other Non-coding RNAs
Other non-coding RNAs appeared deregulated: 128 of all
snoRNAs available in the array corresponded to HAC-Box, with
one downregulated (U71c) and 25 upregulated. A total of 67 of the
274 CD-box snoRNAs were upregulated, and only 5 of the other
499 snoRNAs were upregulated. The scaRNAs were not
deregulated, and the 5.8s rRNAs were upregulated in all 10
copies available at the probeset. The 30 most deregulated non-
coding RNAs are shown in Table 4.
Web-tool Analysis
Using mirWalk, a web-tool that finds gene targets from a given
list of miRNAs, we obtained a set of validated gene targets using
our lists of upregulated and downregulated miRNAs. These lists of
targets, with 1554 and 1597 genes respectively, were analyzed
separately using the DAVID platform, which uses a set of
functional annotation tools to find biological meaning from data
using gene ontology terms, BioCarta, etc. Using these web tools,
the main deregulated pathways identified were vasculature and
nervous system development (Tables S3 and S4).
Table 2. The top 30 downregulated miRNAs obtained by
microarray analysis, ordered by negative fold-change in
schwannomas.
miRNA p-value Fold-Change
hsa-miR-206 2.17E-09 2222.68
hsa-miR-1 3.85E-09 262.96
hsa-miR-10b 4.85E-08 251.58
hsa-miR-183 1.01E-06 225.33
hsa-miR-182 0.00019 224.44
hsa-miR-204 3.57E-06 217.68
hsa-miR-10b* 5.15E-08 214.51
hsa-miR-133b 8.36E-08 211.44
hsa-miR-214 2.59E-05 211.13
hsa-miR-383 7.99E-06 210.03
hsa-miR-223 0.000085 27.73
hsa-miR-148a 0.000486 27.61
hsa-miR-34b 0.005987 27.36
hsa-miR-10a 0.000004 27.31
hsa-miR-486-3p 0.000185 26.58
hsa-miR-509-3p 1.14E-05 26.57
hsa-miR-486-5p 9.88E-05 26.27
hsa-miR-199a-3p 0.002156 25.42
hsa-miR-199b-3p 0.002919 25.33
hsa-miR-133a 4.49E-06 25.18
hsa-miR-214* 0.015433 24.01
hsa-miR-15b 2.10E-05 23.87
hsa-miR-625 3.35E-07 23.76
hsa-miR-143 0.000495 23.74
hsa-miR-138-2* 0.000303 23.59
hsa-miR-183* 2.30E-05 23.55
hsa-miR-143* 0.01991 23.29
hsa-miR-92a-1* 0.01092 23.23
hsa-miR-595 8.73E-05 23.17
hsa-miR-199a-5p 0.02445 23.10
doi:10.1371/journal.pone.0065868.t002
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Microarray Data Correlation versus NF2 Alterations and
22q Allelic Status
We also tested the possibility that grouping schwannomas by
their molecular characteristics such as the presence or not of NF2
mutations or LOH 22q/normal 22q, would result in a statistically
significant subset of over- or under-expressed miRNAs (using the
one-way ANOVA at p,0.05 and at least a 2-fold change).
Fourteen miRNAs matched these criteria, and a number of the
miRNAs displayed statistical significance in several comparisons
(Table S5). These included the presence of 22q LOH vs. normal
constitution (with significant upregulation of miR-195* in miRNAs
with LOH), the presence of sequence alteration by all methods vs.
normal miRNAs (4 miRNAs), sequence alteration exclusively by
PCR/dHPLC vs. normal miRNAs (3 miRNAs), and one or more
detected alterations vs. no detected alterations (9 miRNAs).
Validation by qRT-PCR
Validation of the expression patterns of 11 miRNAs and
SNORD49A obtained through microarray analysis by performing
qRT-PCR (Table 5). In all cases, the trend observed in the
microarrays (upregulation, downregulation or no deregulation)
was confirmed by this technique.
Discussion
In this study, we used 16 schwannomas and 3 control nerves to
analyze the expression levels of miRNAs and other non-coding
RNAs in Affymetrix microarrays. As an alternative for control
purposes, in vitro cultures of Schwann cells may be used.
However, although it is possible to obtain up to 90% purity of
Schwann cells [41], it has been reported that Schwann cells in
cultures modify their native gene expression [42]. Thus, it appears
that peripheral nerve may be a more reliable control in expression
studies, as it has been proved by several reports [20,21,33]. Our
findings showed deregulation in schwannomas of more than 150
miRNAs and a set of other non-coding miRNAs, with special
upregulation of those miRNAs located in the chromosomal 14q
region. Eleven of the miRNAs and 1 snoRNA were validated by
qRT-PCR.
The most downregulated miRNAs in this study include the
myomiRs, composed of three clusters: miR-1-1/miR-133a-2,
miR-1-2/miR-133a-1, and miR-206/miR-133b. These miRNAs
have been identified as typically downregulated in several types of
cancer, such as colorectal cancer and hepatocellular carcinoma
(reviewed in citation [43]). Other miRNAs with reduced
expression in our series included miR-10b, which has also been
associated with other cancers such as gliomas [44], metastatic
breast carcinomas [45] and pancreatic carcinomas [46]; however,
in all of these cases, miR-10b was upregulated [44]. Decreased
expression of this miRNA has been reported to escape senescence
by Argonaute 2 expression in stem cells [47]. The miRNA 183/
182 cluster, which was downregulated in our series, has also been
found to be deregulated in medulloblastoma [48] and prostate
cancer [49], and the cluster has been shown to inhibit cell
proliferation and migration by targeting FGF9 and NTM in
Table 3. Available miRNAs correspond to those miRNAs tested in the microarray.
Chromosome Available miRNAs Up-regulated Down-regulated Total Percentage of deregulation (%)
1 61 14 3 17 27.9
2 23 2 3 5 21.7
3 35 2 2 4 11.4
4 31 0 2 2 6.5
5 30 2 4 6 20.0
6 17 3 2 5 29.4
7 42 4 7 11 26.2
8 27 1 3 4 14.8
9 30 1 4 5 16.7
10 23 1 2 3 13.0
11 38 3 2 5 13.2
12 42 2 0 2 4.8
13 25 0 2 2 8.0
14 81 40 2 42 51.9
15 27 4 1 5 18.5
16 17 4 2 6 35.3
17 48 6 4 10 20.8
18 9 0 3 3 33.3
19 102 9 4 13 12.7
20 19 0 0 0 0.0
21 7 1 0 1 14.3
22 19 0 1 1 5.3
X 89 20 4 24 27.0
Up or downregulation was obtained from those with at least a 2-fold change and p.0.05 when schwannomas and control nerves were compared. Other non-coding
RNAs were not considered in this table.
doi:10.1371/journal.pone.0065868.t003
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Schwann cells [50]. Furthermore, miR-183 has been found to be
capable of regulating Ezrin protein (a member of the family with
similarity to Merlin) in osteosarcoma and lung cancer [51,52]. The
miRNA 183/182 cluster may therefore be involved in Schwan-
noma formation if it plays a similar role in these neoplasms. In
malignant peripheral nerve sheath tumors (MPNSTs), miR-204 is
downregulated [53], in a similar pattern as that found in the
schwannomas in our arrays. As these tumors also developed from
Schwann cells, there may be common features associated with this
particular miRNA that appear to participate in the development of
both neoplasms.
The upregulated miRNAs in our studies include miR-21, which
targets PTEN in non-small cell lung cancer [54]; cluster miR-221/
miR-222, which is activated in Schwann cell proliferation
following sciatic nerve injury by targeting LASS2 [55] and
accelerates proliferation during liver regeneration [56]; and
miR-370, which is capable of reducing NF1 mRNA levels in
acute myeloid leukemia [57] and is also overexpressed in prostate
cancer [58]. Another miRNA with increased expression is miR-
493, which is defined as a tumor suppressor in bladder cancer and
is capable of downregulating FZD4 and RhoC protein expression
[59]. Thus, several of these miRNAs may contribute to the benign
proliferation observed in schwannomas, such as miR-221/miR-
222, due to their demonstrated capacity to affect proliferation and
regeneration in various tissues, including nerve tissue.
Web-tool analysis (performed using DAVID) provides us with
the theoretical results of validated genes affected by miRNA
deregulation (performed with mirWalk) and the pathways and
related components that involve these genes. The DAVID results
showed several processes related to carcinogenesis in the Kyoto
Encyclopedia of Genes and Genomes (KEGG), including
hsa05215:Prostate cancer, hsa05214:Glioma and the
hsa04012:ErbB signaling pathway. However, when the up- or
down-regulated miRNAs we had previously identified were
considered, the findings showed similar deregulated GO-terms
(e.g., GO:0010604 positive regulation of the macromolecule
metabolic process; GO:0051960 regulation of nervous system
development; GO:0051270 regulation of cell motion, etc.).
Therefore, the data obtained from the analysis of our deregulated
miRNAs with these web-tools must be viewed with caution, and
no definitive conclusions should be drawn. This event might be
related to the lack of tissue specificity when selecting deregulated
miRNAs that were validated for target genes. Once more detailed
data are available on this subject, a re-evaluation of the pathways
affected by miRNA interaction may be performed. We previously
analyzed the critical regulatory pathways that are abnormally
expressed in schwannomas by studying the expression levels of 96
tumor-related genes [21]. Those genes coding for proteins related
to apoptosis and angiogenesis and genes related to DNA damage
repair were the most frequently altered.
When the chromosomal location of the abnormally expressed
miRNAs was analyzed, we found a clear upregulation for those
miRNAs located in the chromosomal 14q32 region. Only two
miRNAs, miR-203 and miR-625, had reduced expression, while
approximately 40 miRNAs showed overexpression, including
miR-431, miR-370 and miR-493, as validated by qRT-PCR.
This region involves a large miRNA cluster [60] [61] altered in
several neoplasms such as gliomas (by downregulation) [62] and a
subtype of acute myeloid leukemia (by upregulation) [63].
Consequently, this region also appears to play a pivotal role in
Table 4. The top 30 deregulated non-miRNAs present in the
arrays.
Transcript ID Chr Sequence p-value Fold-Change
HBII-99 20 CDBox 1.14E-07 5.97
14q(II-12) 14 CDBox 6.83E-07 5.41
U48 6 CDBox 7.30E-06 5.05
14q(I-4) 14 CDBox 8.33E-06 5.05
U107 X HAcaBox 2.61E-09 4.95
HBII-180C 19 CDBox 7.09E-09 4.90
14q(II-14) 14 CDBox 2.52E-05 4.85
U43 22 CDBox 3.53E-07 4.46
U31 11 CDBox 3.73E-06 4.42
14q(II-3) 14 CDBox 8.57E-06 4.42
U43 22 CDBox 7.81E-07 4.31
ENSG00000200879 11 snoRNA 7.21E-11 4.24
14q(II-14) 14 CDBox 5.42E-05 4.20
ACA7 3 HAcaBox 3.00E-06 4.09
U46 1 CDBox 7.68E-08 4.06
U8 17 CDBox 1.82E-06 4.02
ACA48 17 HAcaBox 6.70E-07 3.98
ENSG00000202252 11 snoRNA 3.03E-05 3.91
U8 17 CDBox 3.32E-07 3.87
U46 1 CDBox 4.34E-07 3.78
14q(II-26) 14 CDBox 0.00128 3.76
ACA16 1 HAcaBox 7.13E-05 3.70
ENSG00000207118 11 snoRNA 0.00011 3.68
U103 1 CDBox 3.05E-08 3.68
ACA48 17 HAcaBox 1.64E-06 3.61
ACA16 1 HAcaBox 3.75E-06 3.54
HBII-85-8 15 CDBox 3.89E-07 3.49
U33 19 CDBox 4.22E-08 3.44
14q(II-12) 14 CDBox 3.84E-05 3.43
HBII-180A 19 CDBox 5.51E-08 3.43
doi:10.1371/journal.pone.0065868.t004
Table 5. The qRT-PCR showed all miRNAs significantly up or
downregulated in schwannomas compared to control-nerves
(at least a 2-fold change and p.0.05), except in those two
used as house-keeping (SNORD49A and miR-103).
miRNA Location Fold-change P-value
miR-1 20q13.33 126.72 0.0251
miR-10b 2q31.1 269.19 0.0251
miR-133b 6p12.2 210.49 0.0251
miR-183 7q32.2 57.34 0.0251
miR-206 6p12.2 379.28 0.0251
miR-221 Xp11.3 –9.62 0.0251
miR-370 14q32.2 –3.13 0.0364
miR-431 14q32.2 -6.38 0.0251
miR-493 14q32.2 –7.99 0.0251
miR-720 3q26.1 –3.49 0.0364
SNORD49A 17p11.2 1.01 0.7324
miR-103 5q34 –1.01 0.7324
doi:10.1371/journal.pone.0065868.t005
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Schwannoma formation and/or maintenance. On chromosome
22, which usually suffers a loss of heterozygosity in Schwannoma,
5% of the miRNAs located in this region appeared deregulated. In
fact, only miR-185 (at 22q11) displayed reduced expression levels.
This finding suggests that, in schwannomas, losses involving 22q
do not seem to affect the expression pattern of miRNA located
there. However this particular miRNA (miR-185) may be affected
as a result of other yet unknown regulatory molecular mecha-
nisms.
Several deregulated miRNAs we identified concur with the data
from previous reports in schwannomas [32,33]. In agreement with
the data, miR-7, miR-638, miR-143* and miR-498 were
downregulated, and miR-221, miR-21, miR-29, miR-30a and
miR-138 were upregulated in our study. On the other hand, a few
of the miRNAs, such as miR-34a, let-7d and miR-451, did not
match the same trend of aberrant expression as that previously
described. Establishing a reason for these divergences is a difficult
task, because neither the number of samples nor the methodology
used should influence the result. Therefore, our findings generally
concur with the results of previous reports, although several
miRNAs with a different expression pattern were identified.
We found alterations in other non-coding RNAs (snoRNAs and
scaRNAs) using this type of array. These alterations have been
associated with the development or progression of breast cancer
and acute leukemia [64,65]. Our results showed that at least 98 of
these non-coding RNAs were deregulated, almost all by increased
expression, except for HACA-Box SNORA71C. A total of 14
SnoRNAs were also located in chromosome 14q32, highlighting
the paramount role played by the miRNAs located in this genomic
region in Schwannoma development.
Schwannomas with specific molecular characteristics, such as
gene mutations of NF2 and/or LOH of 22q region, may present a
different miRNA expression pattern when compared to unaltered
schwannomas. When comparing levels of miRNA expression
obtained from arrays with other molecular studies performed on
these tumors (NF2 mutation detection or 22q allelic status
determination), we found 14 miRNAs with aberrant expression.
For example, abnormal overexpression of miR-155, which is
associated with schwannomas with no alterations of any sort,
displayed a statistical significance of p,0.001; however, miR-
125b-2* was found to be significantly downregulated in those
tumors carrying a mutation (p,0.01). Despite these differences,
establishing a molecular reason for these particular alterations is
difficult. Furthermore, the p-values were relatively high compared
with those obtained when tumors and controls were studied, and
outliers could not be ruled out as playing a role in these results. We
therefore concluded that, at the miRNA level, a few miRNA
subsets may have relevance depending on the genetic status of the
tumor (the presence of NF2 mutation and/or LOH of 22q),
although more research needs to be conducted on this particular
aspect.
In conclusion, our results show that the non-coding RNA
expression pattern is critically affected in schwannomas when
compared to healthy tissue. Of these, miRNAs seems to be the
most frequently affected, given that at least 20% appear
deregulated, including several depicted in other tumors. These
mRNAs include miR-10b and miR-204. Furthermore, a well-
described cluster of non-coding RNAs in the chromosomal region
14q32 seems to present global upregulation, suggesting that
miRNA deregulation in this region might play a significant role in
the development and/or maintenance of these tumors. Finally,
other non-coding RNAs, although less numerous when compared
with miRNAs, also seem to be altered in schwannomas.
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